Calithera Biosciences Inc. (NASDAQ:CALA) major shareholder Adage Capital Partners Gp, L.L acquired 500,000 shares of the stock in a transaction on Wednesday, November 16th. The stock was bought at an average price of $3.15 per share, for a total transaction of $1,575,000.00. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Shares of Calithera Biosciences Inc. (NASDAQ:CALA) traded up 6.15% on Friday, hitting $3.45. The stock had a trading volume of 200,401 shares. The stock’s market cap is $67.24 million. Calithera Biosciences Inc. has a 12 month low of $2.20 and a 12 month high of $8.85. The firm has a 50 day moving average of $2.95 and a 200 day moving average of $3.59.

Several equities research analysts have commented on CALA shares. Citigroup Inc. started coverage on Calithera Biosciences in a research report on Tuesday, October 25th. They issued a “sell” rating on the stock. JMP Securities restated a “buy” rating on shares of Calithera Biosciences in a research report on Thursday, November 10th. Finally, Zacks Investment Research upgraded Calithera Biosciences from a “hold” rating to a “buy” rating and set a $3.75 price objective on the stock in a research report on Monday. One analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $9.03.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CALA. Jacobs Levy Equity Management Inc. purchased a new position in Calithera Biosciences during the first quarter valued at approximately $218,000. GSA Capital Partners LLP raised its position in Calithera Biosciences by 25.9% in the second quarter. GSA Capital Partners LLP now owns 43,800 shares of the company’s stock valued at $162,000 after buying an additional 9,000 shares during the period. Bridgeway Capital Management Inc. raised its position in Calithera Biosciences by 102.8% in the second quarter. Bridgeway Capital Management Inc. now owns 157,850 shares of the company’s stock valued at $586,000 after buying an additional 80,000 shares during the period. Paloma Partners Management Co purchased a new position in Calithera Biosciences during the second quarter valued at approximately $150,000. Finally, Franklin Street Advisors Inc. NC raised its position in Calithera Biosciences by 18.6% in the third quarter. Franklin Street Advisors Inc. NC now owns 100,000 shares of the company’s stock valued at $325,000 after buying an additional 15,700 shares during the period. 49.81% of the stock is currently owned by institutional investors.

About Calithera Biosciences

Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.

5 Day Chart for NASDAQ:CALA

Receive News & Stock Ratings for Calithera Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences Inc. and related stocks with our FREE daily email newsletter.